Thurman Alex R. sold $1.6M of GKOS

Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 10,000 shares of GLAUKOS Corp (GKOS) at $155.00 ($1.55M total) on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thurman Alex R.
Published Jul 14, 2026, 12:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest concrete fact is the CFO’s open-market sale of 10,000 shares at $155/share, totaling $1.55M, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment, but there is no new fundamental catalyst in the filing.

03

What to watch

Insider sales can be scheduled regardless of company outlook; without accompanying buys or new company disclosures, the trading signal is weak.

Relevance 5/10Novelty 3/10Timing: New SEC Form 4 filed 2026-07-13, covering a sale dated 2026-07-09.

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos Corp, identifying the CFO and the sale details.

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Glaukos CFO Thurman Alex sold 10,000 shares on 2026-07-09 at $155/share under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Likely minimal near-term price impact; any reaction is more sentiment-driven than fundamental.

Evidence & confidence

The filing is an insider transaction (not a guidance, contract, or regulatory event). The presence of a pre-arranged 10b5-1 plan typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider activity without operational or regulatory details.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven and not a bearish signal, especially given the stated 10b5-1 plan.

Key entities

  • GLAUKOS Corp

    Company whose CFO filed the insider sale on Form 4.

  • Thurman Alex R.

    SVP and Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.